Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 2/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.41 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.41 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.41 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.40 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.40 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.39 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15434306 | 1.00 | EPHX1 (0.43) | EPHX1HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL7908772 | 0.85 | EPHX1 (0.41) | EPHX1HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL7908747 | 0.85 | EPHX1 (0.41) | EPHX1HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL30365353 | 0.85 | EPHX1 (0.41) | EPHX1HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL7908751 | 0.85 | EPHX1 (0.41) | EPHX1HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL22322962 | 0.85 | EPHX1 (0.41) | EPHX1HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL4462528 | 0.82 | EPHX1 (0.42) | EPHX1HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL5910306 | 0.82 | KCNQ2 (0.44) | EPHX1HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL25293685 | 0.82 | PTGS1 (0.43) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL14159220 | 0.82 | PTGS1 (0.43) | HDAC3HDAC4HDAC1HDAC7HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3921317-A1 | 3-AMINO-2-[2-(ACYLAMINO)PYRIDIN-4-YL]-1,5,6,7-TETRAHYDRO-4H-PYRROLO[3,2-C]PYRIDIN-4-ONE AS CSNK1 INHIBITORS | Bayer Aktiengesellschaft (DE) | 2021-12-15 | — | — | EP | claimed |
| WO-2020161257-A1 | 3-AMINO-2-[2-(ACYLAMINO)PYRIDIN-4-YL]-1,5,6,7-TETRAHYDRO-4H-PYRROLO[3,2-C]PYRIDIN-4-ONE AS CSNK1 INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2020-08-13 | — | — | WO | claimed |
| EP-4509122-A2 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND THERAPEUTIC USES THEREOF | Bayer Aktiengesellschaft (DE) | 2025-02-19 | — | — | EP | disclosed |
| EP-3004092-B1 | SUBSTITUTED TRIAZOLOPYRIDINES | Bayer Pharma AG (DE) | 2017-03-22 | — | — | EP | disclosed |
| US-20150148542-A1 | METHOD FOR PREPARING SUBSTITUTED TRIAZOLOPYRIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-05-28 | — | — | US | disclosed |
| WO-2014009219-A1 | METHOD FOR PREPARING SUBSTITUTED TRIAZOLOPYRIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150148542-A1 | METHOD FOR PREPARING SUBSTITUTED TRIAZOLOPYRIDINES | QDPR, CYP3A5, CYP3A7 | EPHX1 944/4885HDAC3 2352/4885HDAC4 3187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.